Related Experiment Videos

The J-ALEX trial-is frontline alectinib a new standard of care?

Jeffrey Zweig¹, Heather A Wakelee¹

¹Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

Journal of Thoracic Disease

|September 22, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026

Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].

JTO clinical and research reports·2026

KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.

Cancer treatment and research communications·2026

Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.

British journal of cancer·2026

See all related articles